Publications by authors named "Ted Wells"
Background: Patients with advanced prostate cancer (PC) commonly experience fatigue related to the disease itself and its treatment, which affects their quality of life. There are limited real-world data available on patients' experiences of fatigue while receiving PC treatment and its management.
Patients And Methods: This was a cross-sectional, noninterventional qualitative study involving individual concept-elicitation interviews with patients in the United States.
Article Synopsis
- Acute hepatic porphyria (AHP) is a rare disease that can cause serious attacks and long-lasting symptoms, significantly affecting patients' daily lives and health-related quality of life, particularly in those with frequent attacks.
- This study focused on patients with sporadic AHP attacks, aiming to understand their symptoms during attack-free periods, how often they occur, and their overall impact on life.
- Interviews with 14 participants revealed common chronic symptoms like fatigue and pain, along with challenges in daily activities and mental health issues, highlighting the ongoing burden of the disease, even when not experiencing acute attacks.
Background: Presbyopia is a progressive condition that reduces the eye's ability to focus on near objects with increasing age. After a systematic literature review identified no existing presbyopia-specific patient-reported outcome (PRO) instruments meeting regulatory guidance, a new PRO instrument, the Near Vision Presbyopia Task-based Questionnaire (NVPTQ), was developed.
Results: To explore the patient experience with presbyopia, concept elicitation interviews were conducted with 20 presbyopic participants.
Introduction: Presbyopia is a progressive, age-related visual condition that is characterized by reduced ability to focus on near/close objects, causing impacts on individuals' daily function and health-related quality of life. The Presbyopia Impact and Coping Questionnaire (PICQ) is a new patient-reported outcome (PRO) instrument that assesses presbyopia impact and use of coping behaviors among presbyopic individuals.
Methods: To document the impacts of presbyopia and associated coping behaviors, concept elicitation (CE) interviews were conducted with 20 presbyopic participants.
Introduction: Currently recommended patient-reported outcome (PRO) measures for patients with pyruvate kinase (PK) deficiency are non-disease-specific. The PK Deficiency Diary (PKDD) and PK Deficiency Impact Assessment (PKDIA) were developed to be more targeted measures for capturing the symptoms and impacts of interest to this patient population.
Methods: The instruments were developed based on concept elicitation interviews with 21 adults and modified based on 20 cognitive interviews.
Article Synopsis
- This study investigates the impact of pyruvate kinase (PK) deficiency on health-related quality of life (HRQoL) for patients with this rare hemolytic anemia caused by PKLR gene mutations.
- Through interviews with 21 adults from the United States, Netherlands, and Germany, the study identifies common symptoms such as yellow eyes, fatigue, and shortness of breath, and how these symptoms affect daily activities and overall well-being.
- Conclusions highlight this study as the first to capture the patient perspective on the burden of PK deficiency, setting the stage for future research into treatment effects on HRQoL.
Background: Neuropathic pain (NP) is a complex, chronic pain state initiated by a primary lesion or dysfunction of the nervous system and presents as a variety of symptoms across multiple disease states.
Objective: To develop a patient-centred conceptual model of symptoms and impacts in subjects with diabetic peripheral neuropathy (DPN) or post-herpetic neuralgia (PHN) that can inform the measurement strategy in clinical trials.
Method: Thirty subjects with DPN or PHN participated in in-person interviews which were performed until saturation was achieved.
Human rhinoviruses (HRV) cause the majority of common colds and acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). Effective therapies are urgently needed, but no licensed treatments or vaccines currently exist. Of the 100 identified serotypes, ∼90% bind domain 1 of human intercellular adhesion molecule-1 (ICAM-1) as their cellular receptor, making this an attractive target for development of therapies; however, ICAM-1 domain 1 is also required for host defence and regulation of cell trafficking, principally via its major ligand LFA-1.
View Article and Find Full Text PDF